| Name | Title | Contact Details |
|---|---|---|
Jim Van Duyn |
Chief Information Officer | Profile |
Phil is a B2B2C platform that connects patients, pharmacies, prescribers, and manufacturers in the specialty prescription ecosystem. We build software solutions & end-to-end services to power the $320B industry.
Magellan Medicaid Administration is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OCHN has a long-standing history of promoting independence, choice, and community inclusion for adults and children with intellectual / developmental disabilities, mental health concerns, and substance use disorders. Its mission to “inspire hope, empower people, and strengthen communities” reflects an unyielding belief in a "Valuable System for Valued People." Programs and supports provided by OCHN`s service network are available at www.oaklandchn.org. Most people who receive services through Oakland County`s public mental health system, which is managed by OCHN, have Medicaid insurance coverage.
For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. We are proud of addressing some of the most challenging healthcare issues. Our vision – value through innovation – has always characterized our collaborative work, and is for us simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.